May 1, 2025
LONGEVITY Community Engagement: Perspectives of People with HCV and TB Lived Experience and Healthcare Providers on Potential Long-Acting Therapies
Webinar / Presentation
This webinar will provide a platform to learn about the findings from the Longevity HCV and TB end users and healthcare providers/policy makers surveys, and for community members, especially marginalized populations across the world, to engage with the researchers developing these Long-Acting Therapies.

May 1, 2025
NIH Advocacy Toolkit for HIV & TB Researchers
Publication
The Research Matters Advocacy Toolkit is a vital resource for researchers committed to advancing health equity and biomedical advocacy.

April 30, 2025
Hearing on Biomedical Research – Keeping America’s Edge in Innovation
Letter / Comment
Treatment Action Group (TAG) is issuing an urgent call to protect the integrity of biomedical research and public health.

April 27, 2025
Inside the Fight: A Day in the Life of TAG’s TB Team
What does TAG’s work look like in action? Here we step into a day in the life of our TB program co-directors, Mike Frick and Lindsay McKenna, to see how their advocacy for better TB research and policy — made possible by your support — are driving meaningful change to save lives and empower communities affected by TB.

April 24, 2025
Magic Mountains of Debt: Sovereign Debt Crises as Critical Barriers to Ending TB and Investing in Sustainable Development Goals
Publication
TAG’s Magic Mountains of Debt: Sovereign Debt Crises as Critical Barriers to Ending TB and Investing in Sustainable Development Goals analyzes the impact  of sovereign debt in depressing investments in TB programs, services, and R&D in high-TB burden nations.

April 23, 2025
Speed-Up, Scale-Up TB Testing: A Two-Part Webinar Series Focused on the Asia-Pacific Region
Webinar / Presentation
TAG, APCASO,  and Diagnostics Equity Consortium (DEC) hosted a two-part webinar series exploring the evolving TB diagnostic landscape and strategies to increase TB testing coverage, with a specific focus on the South-East Asia and Western-Pacific regions.

April 23, 2025
Diagnostics Equity Consortium: Close the Deadly TB Testing Gaps in Asia-Pacific
Statement / Press
TAG is one of the endorsers of this Diagnostic Equity Consortium statement and call to action advocating for scaling up access to diagnostics to address the deadly gaps in TB testing.

April 11, 2025
Research Toward a Cure Trials
A listing of clinical trials and observational studies related to the research effort to cure HIV infection, mainly derived from the clinicaltrials.gov online registry. Click the trial registry identifier numbers for a link to the full entry containing detailed information on the trial design, enrollment criteria, principal investigators and location(s).

April 11, 2025
SURVEY EXTENDED: Scoping Community Interventions to Support New TB Vaccine Introduction: From Grassroots Partnerships to Global Policymaking
Survey now extended until April 24! TAG, with support from Wellcome, is conducting a scoping exercise of community partners and interventions to support new TB vaccine readiness.

April 9, 2025
TAG Joins Call for the Resignation of HHS Secretary RFK, Jr., as a “Danger to the Public’s Health”
Statement / Press
Treatment Action Group (TAG) decries the vicious and inchoate attacks on HHS since the advent of the new administration, which have escalated significantly over the past week.

April 4, 2025
Tuberculosis Research at the National Institutes of Health – Saving Lives, Shrinking Costs, Fueling American Jobs and Innovation
Publication
This policy brief describes the crucial role NIH plays in supporting research on new products to prevent, diagnose, and cure TB. This research is especially important at a time when new forms of drug resistance are emerging globally, and rates of TB are rising in the U.S. With continued and increased funding, NIH can protect Americans from the growing threat of TB at home and abroad.

March 28, 2025
An Activist’s Guide to Shorter Treatment for Drug-Resistant Tuberculosis
Publication
The new 2025 update of An Activist’s Guide to Shorter Treatment for Drug-Resistant Tuberculosis lays out what community advocates need to know about WHO-recommended regimens for drug-resistant TB.

March 28, 2025
Community Materials on Drug-Resistant Tuberculosis
Publication
To accompany the updated Activist’s Guide to Shorter Treatment for Drug-Resistant Tuberculosis, TAG also developed three additional educational materials to support community-based and civil society organizations leading treatment literacy, peer support, and community-led monitoring activities:

March 25, 2025
TAG Condemns Plans to Eliminate Vital HIV programs at the CDC’s National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Statement / Press
TAG is deeply concerned about the Trump administration’s potential plans to eliminate vital HIV programs at the CDC’s Division of HIV Prevention (DHP) and other programs in the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP).

March 19, 2025
TAG Launches TB Vaccines Pipeline Report
Publication
TAG is pleased to share the latest edition of our Tuberculosis Vaccines Pipeline Report, written by TB project co-director Mike Frick. The report provides the latest information on 17 vaccine candidates under clinical development and summarizes ongoing, planned, and recently completed clinical trials in two comprehensive tables.

March 18, 2025
TAG Defends Continuing Vital TB and HIV Research in South Africa
Statement / Press
Treatment Action Group (TAG) opposes in the strongest possible terms the termination of National Institutes of Health (NIH) research awards and contracts to South Africa, feared following reporting by Science.

March 7, 2025
Treatment Action Group Opposes the Nomination of Dr. Jay Bhattacharya for Director of the U.S. National Institutes of Health
Statement / Press
The nomination of Dr. Jay Bhattacharya for Director of the United States National Institutes of Health (NIH) continues the pattern of un- and under-qualified nominees put forward by the current administration.

February 27, 2025
HIV Cure Research Information Sheet
Publication
Research into curing HIV infection is ever-changing as new discoveries are made and scientists report additional rare — but informative — cases of individuals likely cured of HIV.

February 26, 2025
ANEA and TAG Stand in Solidarity with Demonstrators Fighting to Save PEPFAR
Statement / Press
The ACT NOW: END AIDS Coalition (ANEA) and Treatment Action Group (TAG) are proud to stand in solidarity with activists demonstrating today at the U.S. Capitol demanding that the U.S. government restore full funding to the President’s Emergency Plan for AIDS Relief (PEPFAR)

February 18, 2025
TAG Fiercely Condemns the New Administration’s War on Science
Statement / Press
Treatment Action Group (TAG) is disgusted and appalled by the new presidential administration’s flagrant attack on science.

February 7, 2025
2025 Pre-CROI Community HIV Cure Research Workshop
Webinar / Presentation
The 2025 Pre-CROI Community HIV Cure Research Workshop will take place on Saturday, March 8 in San Francisco.

February 6, 2025
TAG Joins Allies at State Department to Demand Full Restoration of US Support for Global AIDS Programs
Statement / Press
Treatment Action Group (TAG) fiercely condemns the new presidential administration’s deadly and hateful attack on people living with HIV and their communities at home and around the world.

February 5, 2025
TAG Executive Director Warns: “They Don’t Care If We Live or Die”
This title of this page is one of the quotes by Mark Harrington from his recent appearance on +Life Media with TAG board member Karl Schmid. We rate this video absolutely must watch!

February 4, 2025
Letter Urging Congress to Reject All Proposals to Cut Medicaid
Letter / Comment
TAG was proud to sign on to this 2/3/25 letter created by HIV Health Care Access Working Group (HHCAWG) of the Federal AIDS Policy Partnership (FAPP).

January 29, 2025
Community Surveys Show Enthusiasm for Long-Acting HCV Cure Research
Statement / Press
People living with or at risk of hepatitis C Virus (HCV), health care providers, and policymakers in low- and middle-income countries (LMICs) showed significant interest in a potential long-acting HCV cure, recent surveys have found.